I-Corps: Soil-derived mycobacteria for the treatment of posttraumatic stress disorder (PTSD) and other anxiety disorders

I-Corps：土壤来源的分枝杆菌，用于治疗创伤后应激障碍 (PTSD) 和其他焦虑症

• 批准号: 2051920
• 负责人: Christopher Lowry
• 金额: $ 5万
• 依托单位: University of Colorado at Boulder
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-15 至 2023-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2051920&HistoricalAwards=false
• 关键词: Corps; Soil; derived; mycobacteria; treatment

The broader impact/commercial potential of this I-Corps project is the development of novel therapeutics for the treatment of mental health disorders, specifically, posttraumatic stress disorder (PTSD). While PTSD is most commonly associated with military personnel, it is estimated that roughly 7-8% of Americans will suffer from PTSD at some point in their lives resulting from everyday trauma, such as car accidents and sexual trauma. Further, it is anticipated there will be dramatic increases in the incidence of PTSD as a result of the COVID-19 pandemic. The proposed therapeutics would be most effective as part of an integrative approach to treating PTSD. The proposed innovation is also a fit for the burgeoning complementary and alternative medicine industry. This industry supplements the health needs of roughly 36% of Americans and is estimated to reach $296 billion in global revenues by 2027.This I-Corps project is based on the development and testing of novel strains of mycobacteria that may be incorporated into nutraceuticals for public consumption. Mycobacteria have been shown to reduce inflammation and modify the immune system of the brain. These characteristics of mycobacteria have important implications for mental health. Specifically, it has been shown that administration of heat-killed mycobacteria prior to stress enhances stress resilience and prevents stress-induced exaggeration of inflammation, spontaneous colitis, and anxiety in animal models. These effects specifically address two of the main symptoms of PTSD: avoidance and alterations in excitation or reactivity. These symptoms are associated with well-known behaviors in individuals with PTSD, such as irritability, sleep problems, difficulty concentrating, and avoiding experiences associated with trauma.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

I-Corps项目的更广泛影响/商业潜力是开发治疗精神健康障碍，特别是创伤后应激障碍（PTSD）的新疗法。虽然创伤后应激障碍通常与军人有关，但据估计，大约7-8%的美国人在生活中的某个时候会因日常创伤而患上创伤后应激障碍，比如车祸和性创伤。此外，预计2019冠状病毒病大流行将导致创伤后应激障碍的发病率急剧增加。建议的治疗方法作为治疗创伤后应激障碍综合方法的一部分将是最有效的。拟议中的创新也适合蓬勃发展的补充和替代医学行业。该行业满足了大约36%的美国人的健康需求，预计到2027年全球收入将达到2960亿美元。这个I-Corps项目的基础是开发和测试可能被纳入公众消费的营养保健品的新型分枝杆菌菌株。分枝杆菌已被证明可以减少炎症并改变大脑的免疫系统。分枝杆菌的这些特征对心理健康具有重要意义。具体来说，在动物模型中，研究表明，在应激前施用热杀分枝杆菌可以增强应激恢复能力，防止应激引起的炎症、自发性结肠炎和焦虑的加剧。这些影响特别针对PTSD的两个主要症状：逃避和兴奋或反应性的改变。这些症状与PTSD患者常见的行为有关，如易怒、睡眠问题、注意力难以集中、避免与创伤相关的经历。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。